Aidoc’s AI Radiology System Granted FDA Breakthrough Device Designation
Published on: June 26, 2026
In a development announced on June 25, 2026, the U.S. Food and Drug Administration granted Aidoc’s AI-driven tool, known as First Read, a Breakthrough Device Designation. Designed to analyze chest radiographs and generate high‑quality preliminary report text, the tool aims to support radiologists and enhance imaging workflows amid rising demand and constrained capacity.
Aidoc is a clinical AI company whose tools are already in use at approximately 2,000 hospitals worldwide. The First Read system extends the company’s CARE™ foundation model into the realm of report drafting, marking a notable advance in the application of AI for diagnostic support.
The Breakthrough Device designation by the FDA aims to expedite the development and review of medical devices that provide for more effective treatment or diagnosis of life‑threatening or irreversibly debilitating diseases. For First Read, this status may help accelerate regulatory review and facilitate faster patient access to the tool, though full approval remains required before broader clinical deployment.
Aidoc underscores that imaging interpretation has become a growing bottleneck, with outpatient imaging report turnaround times more than doubling from 2014 to 2023. The company positions First Read as a potential solution to ease these delays and support overburdened radiology departments.
If ultimately approved, First Read could transform how initial radiology assessments are conducted by providing AI‑generated report drafts that radiologists can verify and refine. In doing so, the tool may improve efficiency and mitigate shortages in imaging interpretation capacity, while still ensuring clinician oversight.
No comments yet.